Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment
Abstract Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor involved in regulating cellular antioxidant defense and detoxification mechanisms. It mitigates oxidative stress and xenobiotic-induced damage by inducing the expression of cytoprotective enzymes, including HO-...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-04-01
|
| Series: | Cell Death Discovery |
| Online Access: | https://doi.org/10.1038/s41420-025-02491-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850170878989434880 |
|---|---|
| author | Xinyi Yang Yingchao Liu Jinghao Cao Cuiyun Wu Lusheng Tang Wenxia Bian Yuhan Chen Lingyan Yu Yunyi Wu Sainan Li Yuhuan Shen Jun Xia Jing Du |
| author_facet | Xinyi Yang Yingchao Liu Jinghao Cao Cuiyun Wu Lusheng Tang Wenxia Bian Yuhan Chen Lingyan Yu Yunyi Wu Sainan Li Yuhuan Shen Jun Xia Jing Du |
| author_sort | Xinyi Yang |
| collection | DOAJ |
| description | Abstract Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor involved in regulating cellular antioxidant defense and detoxification mechanisms. It mitigates oxidative stress and xenobiotic-induced damage by inducing the expression of cytoprotective enzymes, including HO-1 and NQO1. NRF2 also modulates inflammatory responses by inhibiting pro-inflammatory genes and mediates cell death pathways, including apoptosis and ferroptosis. Targeting NRF2 offers potential therapeutic avenues for treating various diseases. NRF2 is regulated through two principal mechanisms: post-translational modifications (PTMs) and epigenetic alterations. PTMs, including phosphorylation, ubiquitination, and acetylation, play a pivotal role in modulating NRF2’s stability, activity, and subcellular localization, thereby precisely controlling its function in the antioxidant response. For instance, ubiquitination can lead to NRF2 degradation and reduced antioxidant activity, while deubiquitination enhances its stability and function. Epigenetic modifications, such as DNA methylation, histone modifications, and interactions with non-coding RNAs (e.g., MALAT1, PVT1, MIR4435-2HG, and TUG1), are essential for regulating NRF2 expression by modulating chromatin architecture and gene accessibility. This paper systematically summarizes the molecular mechanisms by which PTMs and epigenetic alterations regulate NRF2, and elucidates its critical role in cellular defense and disease. By analyzing the impact of PTMs, such as phosphorylation, ubiquitination, and acetylation, as well as DNA methylation, histone modifications, and non-coding RNA interactions on NRF2 stability, activity, and expression, the study reveals the complex cellular protection network mediated by NRF2. Furthermore, the paper explores how these regulatory mechanisms affect NRF2’s roles in oxidative stress, inflammation, and cell death, identifying novel therapeutic targets and strategies. This provides new insights into the treatment of NRF2-related diseases, such as cancer, neurodegenerative disorders, and metabolic syndrome. This research deepens our understanding of NRF2’s role in cellular homeostasis and lays the foundation for the development of NRF2-targeted therapies. |
| format | Article |
| id | doaj-art-4a1c0f1bf8b14804a73080e032e44da3 |
| institution | OA Journals |
| issn | 2058-7716 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death Discovery |
| spelling | doaj-art-4a1c0f1bf8b14804a73080e032e44da32025-08-20T02:20:23ZengNature Publishing GroupCell Death Discovery2058-77162025-04-0111111610.1038/s41420-025-02491-zTargeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatmentXinyi Yang0Yingchao Liu1Jinghao Cao2Cuiyun Wu3Lusheng Tang4Wenxia Bian5Yuhan Chen6Lingyan Yu7Yunyi Wu8Sainan Li9Yuhuan Shen10Jun Xia11Jing Du12Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeCancer Center, Department of Radiology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical CollegeAbstract Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor involved in regulating cellular antioxidant defense and detoxification mechanisms. It mitigates oxidative stress and xenobiotic-induced damage by inducing the expression of cytoprotective enzymes, including HO-1 and NQO1. NRF2 also modulates inflammatory responses by inhibiting pro-inflammatory genes and mediates cell death pathways, including apoptosis and ferroptosis. Targeting NRF2 offers potential therapeutic avenues for treating various diseases. NRF2 is regulated through two principal mechanisms: post-translational modifications (PTMs) and epigenetic alterations. PTMs, including phosphorylation, ubiquitination, and acetylation, play a pivotal role in modulating NRF2’s stability, activity, and subcellular localization, thereby precisely controlling its function in the antioxidant response. For instance, ubiquitination can lead to NRF2 degradation and reduced antioxidant activity, while deubiquitination enhances its stability and function. Epigenetic modifications, such as DNA methylation, histone modifications, and interactions with non-coding RNAs (e.g., MALAT1, PVT1, MIR4435-2HG, and TUG1), are essential for regulating NRF2 expression by modulating chromatin architecture and gene accessibility. This paper systematically summarizes the molecular mechanisms by which PTMs and epigenetic alterations regulate NRF2, and elucidates its critical role in cellular defense and disease. By analyzing the impact of PTMs, such as phosphorylation, ubiquitination, and acetylation, as well as DNA methylation, histone modifications, and non-coding RNA interactions on NRF2 stability, activity, and expression, the study reveals the complex cellular protection network mediated by NRF2. Furthermore, the paper explores how these regulatory mechanisms affect NRF2’s roles in oxidative stress, inflammation, and cell death, identifying novel therapeutic targets and strategies. This provides new insights into the treatment of NRF2-related diseases, such as cancer, neurodegenerative disorders, and metabolic syndrome. This research deepens our understanding of NRF2’s role in cellular homeostasis and lays the foundation for the development of NRF2-targeted therapies.https://doi.org/10.1038/s41420-025-02491-z |
| spellingShingle | Xinyi Yang Yingchao Liu Jinghao Cao Cuiyun Wu Lusheng Tang Wenxia Bian Yuhan Chen Lingyan Yu Yunyi Wu Sainan Li Yuhuan Shen Jun Xia Jing Du Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment Cell Death Discovery |
| title | Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment |
| title_full | Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment |
| title_fullStr | Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment |
| title_full_unstemmed | Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment |
| title_short | Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment |
| title_sort | targeting epigenetic and post translational modifications of nrf2 key regulatory factors in disease treatment |
| url | https://doi.org/10.1038/s41420-025-02491-z |
| work_keys_str_mv | AT xinyiyang targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT yingchaoliu targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT jinghaocao targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT cuiyunwu targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT lushengtang targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT wenxiabian targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT yuhanchen targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT lingyanyu targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT yunyiwu targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT sainanli targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT yuhuanshen targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT junxia targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment AT jingdu targetingepigeneticandposttranslationalmodificationsofnrf2keyregulatoryfactorsindiseasetreatment |